OPT 88

Drug Profile

OPT 88

Latest Information Update: 08 Feb 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator The Scripps Research Institute
  • Developer Optimer Biotechnology
  • Class Carbohydrates
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 24 Oct 2013 Discontinued - Preclinical for Osteoarthritis in USA (Intra-articular)
  • 24 Oct 2013 Optimer Pharmaceuticals has been acquired and merged into Cubist Pharmaceuticals
  • 03 Nov 2009 OPT 88 licensed to Optimer Biotechnology Inc.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top